148 related articles for article (PubMed ID: 24977963)
1. Application of ulipristal acetate in female patients with uterine fibroids.
Grzechocinska B; Gadomska H; Zygula A; Wielgos M
Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
[TBL] [Abstract][Full Text] [Related]
2. Safety after extended repeated use of ulipristal acetate for uterine fibroids.
Fauser BC; Donnez J; Bouchard P; Barlow DH; Vázquez F; Arriagada P; Skouby SO; Palacios S; Tomaszewski J; Lemieszczuk B; William AR
PLoS One; 2017; 12(3):e0173523. PubMed ID: 28267814
[TBL] [Abstract][Full Text] [Related]
3. Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma.
Hwang JR; Cho YJ; Ryu JY; Choi JY; Choi JJ; Sa JK; Kim HS; Lee JW
Biomed Pharmacother; 2023 Dec; 168():115792. PubMed ID: 37924789
[TBL] [Abstract][Full Text] [Related]
4. Ulipristal acetate for Japanese women with symptomatic uterine fibroids: A double-blind, randomized, phase II dose-finding study.
Irahara M; Maejima Y; Shinbo N; Yamauchi Y; Mizunuma H
Reprod Med Biol; 2020 Jan; 19(1):65-74. PubMed ID: 31956287
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study.
Nieman LK; Blocker W; Nansel T; Mahoney S; Reynolds J; Blithe D; Wesley R; Armstrong A
Fertil Steril; 2011 Feb; 95(2):767-72.e1-2. PubMed ID: 21055739
[TBL] [Abstract][Full Text] [Related]
6. Long-term intermittent pharmacological therapy of uterine fibroids - a possibility to avoid hysterectomy and its negative consequences.
Olejek A; Olszak-Wąsik K; Czerwinska-Bednarska A
Prz Menopauzalny; 2016 Mar; 15(1):48-51. PubMed ID: 27095959
[TBL] [Abstract][Full Text] [Related]
7. Structural analysis and ensemble docking revealed the binding modes of selected progesterone receptor modulators.
Saritha F; Aiswarya N; Aswath Kumar R; Dileep KV
J Biomol Struct Dyn; 2023; 41(21):12401-12410. PubMed ID: 36752314
[TBL] [Abstract][Full Text] [Related]
8. The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.
Westhoff CL; Guo H; Wang Z; Hibshoosh H; Polaneczky M; Pike MC; Ha R
Breast Cancer Res Treat; 2022 Apr; 192(2):321-329. PubMed ID: 35015210
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of two repeated cycles of ulipristal acetate in the management of symptomatic uterine fibroid among Indian women.
Jha S; Ahmed N; Sinha HH
Prz Menopauzalny; 2021 Sep; 20(3):127-132. PubMed ID: 34703413
[TBL] [Abstract][Full Text] [Related]
10. Experimental and new investigational drugs for the treatment of uterine fibroids.
Evangelisti G; Ferrero S; Perrone U; Gustavino C; Volpi E; Izzotti A; Barra F
Expert Opin Investig Drugs; 2024 Apr; ():1-12. PubMed ID: 38618931
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies in the medical treatment of uterine fibroids.
Goitia M; Estadella J
Med Clin (Barc); 2023 Oct; 161 Suppl 1():S32-S37. PubMed ID: 37923512
[No Abstract] [Full Text] [Related]
12. Advances in uterine fibroid research: Linking progesterone and the TGF-β signaling pathway.
Islam MS
Fertil Steril; 2024 May; ():. PubMed ID: 38729338
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.
Donnez J; Hudecek R; Donnez O; Matule D; Arhendt HJ; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Terrill P; Osterloh I; Loumaye E
Fertil Steril; 2015 Feb; 103(2):519-27.e3. PubMed ID: 25542821
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence.
Trefoux Bourdet A; Luton D; Koskas M
Int J Womens Health; 2015; 7():321-30. PubMed ID: 25848323
[TBL] [Abstract][Full Text] [Related]
15. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
16. Ulipristal acetate in uterine fibroids.
Galliano D
Fertil Steril; 2015 Feb; 103(2):359-60. PubMed ID: 25555419
[No Abstract] [Full Text] [Related]
17. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
18. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids.
Luyckx M; Squifflet JL; Jadoul P; Votino R; Dolmans MM; Donnez J
Fertil Steril; 2014 Nov; 102(5):1404-9. PubMed ID: 25241376
[TBL] [Abstract][Full Text] [Related]
19. Contemporary management of uterine fibroids: focus on emerging medical treatments.
Singh SS; Belland L
Curr Med Res Opin; 2015 Jan; 31(1):1-12. PubMed ID: 25365466
[TBL] [Abstract][Full Text] [Related]
20. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.
Pohl O; Zobrist RH; Gotteland JP
Reprod Sci; 2015 Apr; 22(4):476-83. PubMed ID: 25228633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
